3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gynecologic
4
Genitourinary
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Melanoma
2
Carcinoma, Renal Cell
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Anus Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
28
Cyclophosphamide
14
Nivolumab
13
Paclitaxel
7
fludarabine
6
Specimen Handling
5
aldesleukin
4
Taxes
4
Ipilimumab
4
Interleukin-2
4
Gemcitabine
4
Drug Therapy
4
Docetaxel
4
Carboplatin
4
Bevacizumab
4
poly ICLC
3
liposomal doxorubicin
3
epacadostat
3
cobimetinib
3
cemiplimab
3
Magnetic Resonance Spectroscopy
3
Injections
3
Cisplatin
3
veliparib
2
ulixertinib
2
sargramostim
2
pertuzumab
2
pegilodecakin
2
pazopanib
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
trastuzumab deruxtecan
×
Dermatologic
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled